A biotechnology company plans to add more than 100 new jobs at its facility in southern Wisconsin.
The Wisconsin State Journal reports that New Jersey-based Catalent announced Monday a nearly $100 million investment to expand Catalent Biologics Madison over the next three years. The company develops and manufactures pharmaceutical products made from living cells instead of chemicals at the Madison facility.
Catalent announced a similar investment this week at its facility in Bloomington, Indiana.
Stay informed on the latest news
Sign up for WPR’s email newsletter.
It will be the second expansion of operations at Catalent Biologics Madison in about two years.
Catalent Biologics spokesman Bernie Clark said the latest project will build a 60,000-square-foot addition at the Madison site. It’s expected to be complete by 2021.
Clark said the site is already hiring for dozens of open positions.
© Copyright 2024 by The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
